<!DOCTYPE html><html><head><title>Technical update on pessary use.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Guideline Title
</h3>
<div class='FieldValue'>
<div class="content_title">Technical update on pessary use.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Robert M, Schulz JA, Harvey MA. Technical update on pessary use. J Obstet Gynaecol Can. 2013 Jul;35(7 eSuppl):S1-11. [54 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Recommendations
</h2>
<div class='field field_text'>
<h3>
Major Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The quality of evidence <strong>(I-III)</strong> and classification of recommendations <strong>(A-E, L)</strong> are defined at the end of the "Major Recommendations."</p>
<p><strong>Summary Statements</strong></p>
<ul style="list-style-type: disc;">
    <li>Most women can be successfully fitted with a pessary when they present with prolapse. <strong>(II-2)</strong> </li>
    <li>Complications of pessary use are usually minor, and vaginal discharge is the most common complaint. <strong>(II-3)</strong> </li>
    <li>Vaginal erosions can be treated with removal of the pessary and optional vaginal estrogen supplementation. <strong>(II-2)</strong> </li>
    <li>Satisfaction rates with pessary use are very high. <strong>(II-2)</strong> </li>
</ul>
<p><strong>Recommendation</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Pessaries should be considered in all women presenting with symptomatic prolapse and/or urinary stress incontinence. <strong>(II-1A)</strong> </li>
</ol>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong>:</p>
<p><strong>Quality of Evidence Assessment*</strong></p>
<p><strong>I</strong>: Evidence obtained from at least one properly randomized controlled trial</p>
<p><strong>II-1</strong>: Evidence from well-designed controlled trials without randomization</p>
<p><strong>II-2</strong>: Evidence from well-designed cohort (prospective or retrospective) or case&ndash;control studies, preferably from more than one centre or research group</p>
<p><strong>II-3</strong>: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category</p>
<p><strong>III</strong>: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees</p>
<p class="Note">* Adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.</p>
<p><strong>Classification of Recommendations&dagger;</strong></p>
<p><strong>A.</strong> There is good evidence to recommend the clinical preventive action</p>
<p><strong>B.</strong> There is fair evidence to recommend the clinical preventive action</p>
<p><strong>C.</strong> The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making</p>
<p><strong>D.</strong> There is fair evidence to recommend against the clinical preventive action</p>
<p><strong>E.</strong> There is good evidence to recommend against the clinical preventive action</p>
<p><strong>L.</strong> There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making</p>
<p class="Note">&dagger; Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Clinical Algorithm(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>None provided</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Scope
</h2>
<div class='field field_text'>
<h3>
Disease/Condition(s)
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Pelvic organ prolapse </li>
    <li>Urinary stress incontinence </li>
</ul>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Guideline Category
</h3>
<div class='FieldValue'>
Counseling
</div>
<div class='FieldValue'>
Diagnosis
</div>
<div class='FieldValue'>
Evaluation
</div>
<div class='FieldValue'>
Management
</div>
<div class='FieldValue'>
Treatment
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Clinical Specialty
</h3>
<div class='FieldValue'>
Obstetrics and Gynecology
</div>
<div class='FieldValue'>
Urology
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Intended Users
</h3>
<div class='FieldValue'>
Advanced Practice Nurses
</div>
<div class='FieldValue'>
Nurses
</div>
<div class='FieldValue'>
Physician Assistants
</div>
<div class='FieldValue'>
Physicians
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Objective(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>To review the use, care, and fitting of pessaries</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Target Population
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Women presenting with prolapse and/or urinary incontinence</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Interventions and Practices Considered
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Pessary use, care and fitting</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Major Outcomes Considered
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Accuracy of fit </li>
    <li>Incidence and severity of complications </li>
    <li>Patient satisfaction </li>
    <li>Quality of life </li>
    <li>Symptom relief </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Methodology
</h2>
<div class='field field_picklist-many'>
<h3>
Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
Searches of Electronic Databases
</div>
<div class='FieldValue'>
Searches of Unpublished Data
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>PubMed and Medline were searched for articles published in English to September 2010, using the key words pessary, prolapse, incontinence, fitting, and complications. Results were restricted to systematic reviews, randomized control trials (RCTs)/controlled clinical trials, and observational studies. Searches were updated on a regular basis, and articles were incorporated in the guideline to May 2012. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Number of Source Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Assess the Quality and Strength of the Evidence
</h3>
<div class='FieldValue'>
Weighting According to a Rating Scheme (Scheme Given)
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Quality of Evidence Assessment*</strong></p>
<p><strong>I</strong>: Evidence obtained from at least one properly randomized controlled trial</p>
<p><strong>II-1</strong>: Evidence from well-designed controlled trials without randomization</p>
<p><strong>II-2</strong>: Evidence from well-designed cohort (prospective or retrospective) or case&ndash;control studies, preferably from more than one centre or research group</p>
<p><strong>II-3</strong>: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category</p>
<p><strong>III</strong>: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees</p>
<p class="Note">* Adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
Systematic Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of the Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The quality of evidence was rated with use of the criteria described by the Canadian Task Force on Preventive Health Care. Recommendations for practice were ranked according to the method described by the Task Force (see the "Rating Scheme for the Strength of the Evidence" and the "Rating Scheme for the Strength of the Recommendations" fields).</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
Expert Consensus
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not stated</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Classification of Recommendations&dagger;</strong></p>
<p><strong>A.</strong> There is good evidence to recommend the clinical preventive action</p>
<p><strong>B.</strong> There is fair evidence to recommend the clinical preventive action</p>
<p><strong>C.</strong> The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making</p>
<p><strong>D.</strong> There is fair evidence to recommend against the clinical preventive action</p>
<p><strong>E.</strong> There is good evidence to recommend against the clinical preventive action</p>
<p><strong>L.</strong> There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making</p>
<p class="Note">&dagger; Adapted from the Classification of Recommendations criteria described in the Canadian Task Force on Preventive Health Care.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Cost Analysis
</h3>
<div class='FieldValue'>
<div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Method of Guideline Validation
</h3>
<div class='FieldValue'>
Internal Peer Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of Method of Guideline Validation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This technical update has been prepared by the Urogynaecology Committee, reviewed by the Family Practice Advisory Committee, and approved by the Executive of the Society of Obstetricians and Gynaecologists of Canada.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Recommendations
</h2>
<div class='field field_text'>
<h3>
Type of Evidence Supporting the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Benefits/Harms of Implementing the Guideline Recommendations
</h2>
<div class='field field_text'>
<h3>
Potential Benefits
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Appropriate management of pessary use in women with pelvic organ prolapse and/or urinary stress incontinence.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Potential Harms
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Minor complications of pessary use such as vaginal discharge, odour, and erosions can usually be successfully treated. </li>
    <li>Major complications have been seen only with neglected pessaries. In case reports documenting complications including vesicovaginal fistulae, bowel fistulae, incarcerated pessaries, 91% were related to neglected pessaries. </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Qualifying Statements
</h2>
<div class='field field_text'>
<h3>
Qualifying Statements
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the Society of Obstetricians and Gynaecologists of Canada (SOGC).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Implementation of the Guideline
</h2>
<div class='field field_text'>
<h3>
Description of Implementation Strategy
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An implementation strategy was not provided.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Implementation Tools
</h3>
<div class='FieldValue'>
Chart Documentation/Checklists/Forms
</div>
<div class='FieldValue'>
Foreign Language Translations
</div>
<div class='FieldValue'>
Patient Resources
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-many'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Getting Better
</div>
<div class='FieldValue'>
Staying Healthy
</div>

</div>
<div class='field field_picklist-many'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Patient-centeredness
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information and Availability
</h2>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Robert M, Schulz JA, Harvey MA. Technical update on pessary use. J Obstet Gynaecol Can. 2013 Jul;35(7 eSuppl):S1-11. [54 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date Released
</h3>
<div class='FieldValue'>
2013 Jul
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Guideline Developer(s)
</h3>
<div class='FieldValue'>
Society of Obstetricians and Gynaecologists of Canada - Medical Specialty Society
</div>

</div>
<div class='field field_text'>
<h3>
Source(s) of Funding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Society of Obstetricians and Gynaecologists of Canada (SOGC)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Committee
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Urogynaecology Committee</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of Group That Authored the Guideline
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Principal Authors</em>: Magali Robert, MD, Calgary AB; Jane A. Schulz, MD, Edmonton AB; Marie-Andr&eacute;e Harvey, MD, Kingston ON</p>
<p><em>Urogynaecology Committee</em>: Danny Lovatsis, MD (<em>Co-Chair</em>), Toronto ON; Jens-Erik Walter, MD (<em>Co-Chair</em>), Montreal QC; Queena Chou, MD, London ON; William A. Easton, MD, Scarborough ON; Annette Epp, MD, Saskatoon SK; Scott A. Farrell, MD, Halifax NS; Roxana Geoffrion, MD, Vancouver BC; Lise Girouard, RN, Winnipeg MB; Chander K. Gupta, MD, Winnipeg MB; Marie-Andr&eacute;e Harvey, MD, Kingston ON; Annick Larochelle, MD, St-Lambert QC; Kenny D. Maslow, MD, Winnipeg MB; Grace Neustaeder, RN, Calgary AB; Dante Pascali, MD, Ottawa ON; Marianne Pierce, MD, Halifax NS; Magali Robert, MD, Calgary AB; Sue Ross, PhD, Calgary AB; Joyce Schachter, MD, Ottawa ON; Jane A. Schulz, MD, Edmonton AB; Vyta Senikas, MD, Ottawa ON; David H.L. Wilkie, MD, Vancouver BC</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Disclosure statements have been received from all contributors.</p>
<p>Scott Farrell is Vice-President Medical and a major stakeholder of EastMed Inc. (Halifax, NS), the company marketing Uresta.</p>
<p>Roxana Geoffrion is a shareholder of EastMed Inc.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Electronic copies: Available from the <a href="http://sogc.org/guidelines/technical-update-on-pessary-use/" title="SOGC Web site">Society of Obstetricians and Gynaecologists of Canada (SOGC) Web site</a>. Also available in French from the <a href="http://sogc.org/fr/guidelines/technical-update-on-pessary-use/" title="SOGC Web site">SOGC Web site</a>.</p>
<p>Print copies: Available from the Society of Obstetricians and Gynaecologists of Canada, La soci&eacute;t&eacute; des obst&eacute;triciens et gyn&eacute;cologues du Canada (SOGC) 780 promenade Echo Drive Ottawa, ON K1S 5R7 (Canada); Phone: 1-800-561-2416.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Availability of Companion Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The appendix of the <a href="http://sogc.org/guidelines/technical-update-on-pessary-use/" title="SOGC Web site">original guideline document</a> contains a sample patient care guideline and information sheet on pessary care guidelines and follow-up.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Patient Resources
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Urinary incontinence. Women's health information. Electronic copies: Available from the <a href="http://sogc.org/publications/urinary-incontinence/" title="SOGC Web site">Society of Obstetricians and Gynaecologists of Canada (SOGC) Web site</a>. Also available in French from the <a href="http://sogc.org/fr/publications/incontinence-urinaire/" title="SOGC Web site">SOGC Web site</a>. </li>
</ul>
<p class="Disclaimer">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NGC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary was completed by ECRI Institute on September 27, 2013. The information was verified by the guideline developer on October 30, 2013.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NGC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>
</div>

</div>

</div>
</body></html>